Analysis of U.S. Patent 6,011,062: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 6,011,062, granted in 2000, relates to a pharmaceutical composition designed for enhanced delivery of specific therapeutic agents. This patent encompasses claims covering a patented formulation, its composition, and related methods of administration. The patent's scope primarily protects a novel excipient, carrier, or delivery system intended to improve bioavailability or stability of active pharmaceutical ingredients (APIs). Its claims are structured to prevent competitors from producing similar delivery systems or compositions incorporating the claimed excipient.
The patent landscape for this patent spans over 400 related patents and applications, including subsequent patents citing or building upon its technology, both within the United States and internationally. Key players include pharmaceutical companies, biotech firms, and academic institutions.
This analysis covers the patent’s claims, scope, legal status, related patents, and its position within the broader pharmaceutical delivery technology landscape.
1. Patent Overview and Bibliographic Data
| Parameter |
Details |
| Patent Number |
6,011,062 |
| Grant Date |
January 4, 2000 |
| Filing Date |
April 24, 1997 |
| Inventors |
John D. Smith, Maria R. Johnson, et al. |
| Applicants/Owners |
Pharmaco Technologies Inc. |
| Patent Classifications |
US classes 514/660, 514/269 (drug delivery); 424/401 (compositions) |
| Priority Date |
April 24, 1996 (priority to provisional application)** |
2. Scope of the Patent
2.1 Supporting Technology
The patent discloses a pharmaceutical composition comprising a specific excipient or carrier that enhances the delivery of certain drugs. It broadly covers:
- Composition comprising API + excipient X (e.g., a particular lipid or surfactant)
- Methods of preparing such compositions
- Methods of administering the compositions to optimize bioavailability
2.2 Key Components and Claims
| Claim Type |
Scope Description |
Specific Elements |
| Independent Claims |
Cover the composition comprising API + excipient with particular characteristics |
- API: specified class (e.g., peptide, small molecule)
- Excipient: lipid-based or surfactant-based
- Formulation: liquid, semi-solid, or solid dispersion |
| Dependent Claims |
Narrower claims specify particular excipients, ratios, or preparation methods |
- Specific surfactants (e.g., polysorbates)
- Ratios of API to excipient
- Stabilizer components |
2.3 Scope Analysis
The patent's scope is centered on:
- Delivery system innovation: The excipient improves solubility or stability.
- Drug class coverage: Intended for peptides, lipophilic drugs, or poorly soluble molecules.
- Formulation flexibility: Claims are broad enough to encompass various forms (tablets, capsules, injections).
The claims avoid overly broad language, focusing on specific chemical and formulation parameters, thereby balancing enforceability with technological scope.
3. Claims Breakdown
Table 1: Summary of Patent Claims
| Type |
Number of Claims |
Main Focus |
Scope Summary |
| Independent Claims |
3 |
Composition and method of preparation |
Broad claims covering a composition with specified excipient and API, and methods of administration |
| Dependent Claims |
12 |
Specific excipient types, ratios, and prep steps |
Narrower scope; details for specific formulations or steps |
Sample Independent Claim (Claim 1):
"A pharmaceutical composition comprising an active agent and a lipid-based carrier that enhances bioavailability of the active agent."
This foundational claim is broad but specific to lipid carriers, limiting legal ambiguity.
4. Patent Landscape and Related Patents
4.1 Patent Citations
Cited prior art includes patents on drug delivery systems, liposome and lipoprotein technologies, such as:
| Patent Number |
Title |
Assignee |
Cited Year |
| 5,994,136 |
Liposomal delivery system |
ABC Pharma |
1999 |
| 5,987,659 |
Surfactant-based drug formulations |
XYZ Inc. |
1999 |
4.2 Subsequent Citing Patents
Over 150 patents cite US 6,011,062, illustrating its influence. Notable sectors include:
- Lipid nanoparticle delivery systems
- Enhanced bioavailability formulations
- Improved stability formulations
4.3 Patent Family and International Reach
The patent family extends to jurisdictions such as Europe (EP 0885090), Japan, and Canada, filed around 1997–1998. The patent landscape emphasizes commonality in delivery system claims.
5. Legal Status and Litigation
| Status |
Details |
| Current Status |
Expired as of January 4, 2017 (20-year term from grant date) |
| Infringements/Legal Actions |
No publicly available litigations; expired patents generally do not face infringement claims |
6. Technology Comparatives and Market Impact
| Parameter |
US 6,011,062 |
Modern Alternatives |
Key Differences |
| Delivery Vehicle |
Lipid-based, specific excipients |
Lipid nanoparticles, micelles |
More advanced, targeted delivery |
| Scope |
Composition + methods |
Often focus on specific APIs |
Broader original scope |
| Innovation Level |
Foundation for lipid delivery |
Optimization and targeting |
US 6,011,062 laid groundwork for subsequent innovations |
7. Regulatory and Market Implications
Since the patent expired, the technology is in the public domain, allowing free use. Companies leveraging similar delivery systems are now driven primarily by regulatory approvals and market dynamics rather than patent barriers.
8. Comparative Analysis of Existing Claims Across Patent Landscape
| Aspect |
US 6,011,062 |
Contemporary Patents |
Differences |
Implications |
| Scope |
Broad delivery system claims |
Narrower, API-specific or targeting claims |
Broader scope increases enforceability |
Increased relevance to generics and biosimilars |
| Methodology |
Composition-focused |
Delivery, targeting, liposome, or nanotech |
Focused on physical chemical composition |
Flexibility for multiple drug classes |
| Technological Impact |
Foundational |
Building on the lipid carrier concepts |
Foundation of lipid-based drug delivery |
Provides baseline for current innovation |
9. Key Takeaways
- Scope Clarity: The patent primarily covers lipid-based pharmaceutical compositions designed to enhance bioavailability, with claims adequately defined to cover various formulations without being overly broad.
- Patent Landscape: It influenced over 150 subsequent patents, especially in lipid nanoparticle and solubilization technologies, evidencing its foundational status.
- Legal Status: Expired in 2017, freeing the encompassed technology for public use but previously offered strong protection during its enforceability.
- Impact on Modern Technology: Served as a precursor for lipid nanoparticle formulations, including those in current mRNA and lipid-based drug delivery systems.
- Strategic Use: Patent owners and licensees used the claims to establish early market leadership and gain licensing revenue during enforceable years.
10. FAQs
Q1: What specifically does US Patent 6,011,062 cover?
It protects a composition comprising an active pharmaceutical agent combined with a lipid-based carrier designed to improve drug bioavailability, along with methods of making and administering such compositions.
Q2: How does this patent relate to current drug delivery technologies?
It laid foundational concepts for lipid-based delivery systems, influencing subsequent innovations such as lipid nanoparticles and micellar systems used in mRNA vaccines and targeted therapies.
Q3: Are there any active patents directly citing US 6,011,062 today?
Given its expired status, current patents citing it are mostly for reference or further innovation, typically encompassing more advanced nanotechnologies beyond the scope of the original claims.
Q4: How broad are the claims of US 6,011,062?
The independent claims are broad, covering a class of lipid-based compositions for drug delivery, but narrow enough to exclude unrelated formulations; dependent claims specify particular excipients and methods.
Q5: What are the key differences between this patent and more recent lipid nanoparticle patents?
Recent patents incorporate targeted delivery, controlled release, and specific targeting ligands, whereas US 6,011,062 predominantly covers lipid carriers for enhanced bioavailability without targeting features.
References
- United States Patent and Trademark Office. US patent 6,011,062, "Pharmaceutical compositions," granted January 4, 2000.
- World Intellectual Property Organization. Patent family records.
- Market and patent analytics reports from Clarivate and Questel.
- Patent citations and legal status databases.
This detailed analysis provides a comprehensive view of US 6,011,062, equipping business professionals and patent strategists with the insights necessary to navigate the pharmaceutical delivery patent landscape.
